“…Despite skepticism in the field (Catts & O'Toole, 2017; Correll, Rubio, & Kane, 2018; Goff et al, 2017; Leucht & Davis, 2017), a major factor, among multiple other possible factors, that may be contributing to the negative outcomes in patients experiencing long-term antipsychotic treatment is antipsychotic-induced dopamine super-sensitivity psychosis (aiDSP) (Chouinard et al, 2017; Fallon, Dursun, & Deakin, 2012; Murray & Di Forti, 2018; Nakata, Kanahara, & Iyo, 2017; Yin, Barr, Ramos-Miguel, & Procyshyn, 2017). The Chicago Follow-up Study was completed before clinical scales for assessing aiDSP had been fully developed (Demjaha, Murray, McGuire, Kapur, & Howes, 2012; Oda, Kanahara, & Iyo, 2015; Suzuki et al, 2015; Vita et al, 2019), and then used in large scale follow-up studies of continuous antipsychotic treatment showing that 30% of patients with schizophrenia and 70% of patients with treatment-resistant schizophrenia developed aiDSP (Chouinard & Chouinard, 2008; Takase et al, 2015).…”